Tag: organ

– EZMEKLY is the first and only therapy to receive marketing authorization in the EU for both adults and children (≥2 years) with NF1-PN, a rare genetic disorder with debilitating symptoms –

– EZMEKLY is the first and only therapy to receive marketing authorization in the EU for both adults and children (≥2 years) with NF1-PN, a rare genetic disorder with debilitating symptoms –

NEW YORK, July 16, 2025 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ: APM) ("Aptorum Group," “Aptorum” or the "Company"), a clinical stage biopharmaceutical company dedicated to addressing unmet medical needs in oncology  and infectious diseases, and DiamiR Biosciences (“DiamiR”), a developer of proprietary innovative blood-based tests for brain health and other diseases with a CLIA licensed, CAP accredited clinical laboratory in New Haven, CT, today announced that they have entered into a definitive agreement for an all-stock merger transaction, in which DiamiR Biosciences will retain its name and become a wholly-owned subsidiary of Aptorum Group upon consummation of the merger.The combined company expects to remain listed on the Nasdaq Stock Market following the closing of the merger.

XIAMEN, China, July 16, 2025 (GLOBE NEWSWIRE) -- From July 12 to 21, Gulangyu, Xiamen, China, hosted the 6th Gulangyu Music Festival. Guided by the Xiamen Municipal People’s Government and co-organized by the Administrative Committee of Xiamen Gulangyu-Wanshishan Scenic Area, Xiamen Municipal Bureau of Culture and Tourism, Xiamen Federation of Literary and Art Circles, Siming District People’s Government of Xiamen, and Xiamen Media Group, this UNESCO World Heritage Site—renowned as the "Piano Island"—centered around the theme "Our music, Our Island," and staged nearly 100 performances over ten days. The diverse program featured opera, organ, piano, pop, and more, inviting global music enthusiasts.

Payer coverage for Emrosi™ now available for 65% of commercial lives, up from 29% in May 2025

– Absence of neurotoxicity of any grade in low-volume disease to-date –

DENVER, July 10, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, today announced it has entered into a definitive agreement for the issuance and sale of an aggregate of 5,242,464 shares of its common stock (or common stock equivalents in lieu thereof) at a purchase price of $0.763 per share of common stock (or per common stock equivalent in lieu thereof), in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, SeaStar Medical will issue and sell unregistered warrants to purchase up to 5,242,464 shares of common stock. The warrants will have an exercise price of $0.638 per share, will be exercisable immediately upon issuance and will expire five years following the effective date of the resale registration statement registering the shares of common stock issuable upon exercise of the warrants.